Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.

Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion.

Blueprint, based in Cambridge, has an approved drug called Ayvakit that treats a rare immunological condition.